BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Cancer

FAK inhibitors reported in Plastech Pharmaceutical Technology patent

July 25, 2024
Plastech Pharmaceutical Technology Co. Ltd. has developed new fused tricyclic derivative acting as focal adhesion kinase (FAK) inhibitors.
Read More
Cancer

Genechem patents new gemcitabine conjugates

July 25, 2024
Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.
Read More
Cancer

Medipol Ueniversitesi Zonguldak Buelent Ecevit University patent discloses specific arylidene barbiturate derivatives

July 25, 2024
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.
Read More
Cancer

Shanghai Wennai Pharmaceutical Technology synthesizes new CYP11A1 inhibitors

July 25, 2024
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.
Read More

US PTO revisits subject matter eligibility for AI

July 24, 2024
By Mark McCarty
The U.S. Patent and Trademark Office has provided updated guidance on the question of patent subject matter eligibility for inventions that rely on artificial intelligence, stating that a patent claim that does little more than recite an abstract idea is not subject-matter eligible.
Read More
Neurology/psychiatric

Chengdu Mfs Pharma identifies analgesic agents

July 24, 2024
Chengdu Mfs Pharma Co. Ltd. has disclosed substituted phenol derivatives potentially useful as analgesics, sedatives, hypnotics and anesthetics.
Read More
Inflammatory

Astrazeneca and Mitsubishi Tanabe Pharma jointly develop NLRP3 inflammasome inhibitors

July 24, 2024
A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
Read More
Neurology/psychiatric

Intra-Cellular Therapies discloses new 5-HT2A receptor ligands for neurological disorders

July 24, 2024
Work at Intra-Cellular Therapies Inc. has led to the identification of heterocycle fused gamma-carbolines characterized as 5-HT2A receptor ligands reported to be useful for the treatment of neurological disorders.
Read More
Inflammatory

Apichope Pharmaceutical and collaborators patent GPR84 antagonists

July 24, 2024
Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have jointly patented tricyclic compounds acting as G-protein coupled receptor 84 (GPR84) antagonists.
Read More
Inflammatory

Roche patent describes new SIK inhibitors

July 24, 2024
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized new benzimidazole derivatives acting as serine/threonine-protein kinase SIK inhibitors.
Read More
Previous 1 2 … 209 210 211 212 213 214 215 216 217 … 3791 3792 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • Skin irritation on hands

    HX-16108 holds promise for treating inflammatory skin diseases

    BioWorld Science
    Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing